Carcinosarcoma Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Carcinosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 1

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Metastatic Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8+8 more
National Cancer Institute (NCI)42 enrolled6 locationsNCT05691504
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 2

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

Carcinoma, Small CellNeuroendocrine TumorsGastrointestinal Stromal Tumors+11 more
Centre Oscar Lambret88 enrolled3 locationsNCT05500391
Recruiting
Phase 1

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic12 enrolled1 locationNCT06483048
Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Metastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Lung Non-Small Cell Carcinoma+24 more
Mayo Clinic324 enrolled3 locationsNCT06349642
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Ovarian CancerEndometrial CancerTriple Negative Breast Cancer(TNBC)+4 more
NiKang Therapeutics, Inc.205 enrolled14 locationsNCT07029399
Recruiting

GISAR German Interdisciplinary Sarcoma Registry

SarcomaSarcoma,Soft TissueSarcoma of Bone+1 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest9,000 enrolled21 locationsNCT04122872
Recruiting
Phase 1

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Endometrial CancerMetastasisEndometrial Endometrioid Adenocarcinoma+5 more
UNC Lineberger Comprehensive Cancer Center58 enrolled1 locationNCT05542407
Recruiting
Phase 2Phase 3

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Ovarian CarcinosarcomaEndometrial Carcinosarcoma
ARCAGY/ GINECO GROUP138 enrolled36 locationsNCT03651206
Recruiting
Phase 3

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

Endometrial Clear Cell AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Serous Adenocarcinoma+6 more
University of Utah188 enrolled5 locationsNCT03422198
Recruiting
Phase 1Phase 2

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Triple-Negative Breast CancerAdvanced Solid TumorHead and Neck Squamous Cell Carcinoma+7 more
Volastra Therapeutics, Inc.200 enrolled14 locationsNCT05902988
Recruiting

Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers

Malignant Uterine NeoplasmEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+3 more
M.D. Anderson Cancer Center1,000 enrolled1 locationNCT05049538
Recruiting
Phase 3

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
NRG Oncology428 enrolled54 locationsNCT05646316
Recruiting
Phase 2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Advanced Ovarian CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Primary Peritoneal Carcinoma+15 more
Mayo Clinic78 enrolled3 locationsNCT06639074
Recruiting

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

CholangiocarcinomaHepatoblastomaFibrolamellar Carcinoma+7 more
Federation Francophone de Cancerologie Digestive150 enrolled40 locationsNCT06541652
Recruiting
Phase 1Phase 2

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic40 enrolled3 locationsNCT05920798
Recruiting
Phase 2

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+12 more
Roswell Park Cancer Institute60 enrolled1 locationNCT04919629